The Faculty of Medicine: Innovation Changing Lives
Prof. Emanual Hanski of the Institute for Medical Research Israel-Canada and doctoral student Moshe Baruch, working with an international research team, have discovered a novel mechanism that influences the Group A streptococcus (GAS) bacterium to become deadly at the early stages of infection. Their findings may lead to the development of new treatments for bacterial infections.
In a joint project led by Dr. Ehud Cohen and his team at the Institute for Medical Research Israel-Canada (IMRIC) and startup company TyrNovo, a novel compound was found to selectively inhibit the aging process without affecting lifespan — thereby, holding promise for the development of drugs for diseases like Alzheimer's, Parkinson's and Huntington's.More
Hebrew University President Menahem Ben-Sasson signed a research agreement with The Children's Hospital of Philadelphia CEO Steven M. Altschuler and Drexel University President John A. Fry as part of Philadelphia Mayor Michael A. Nutter's trade mission to Israel. Research will focus on the advancement of pediatric medicine and pediatric translational research.More
The School of Pharmacy’s new center for pharmaceutical research and drug therapy in children will be one of four such centers in the world. Announced during the School’s recent 60th anniversary celebrations, the center will address the need to develop research tools and specific drug therapies that are appropriate for infants and children. “Our goal is to solve problems that currently have no solution and are not being actively researched," says School of Pharmacy Director Prof. Simon Benita.More
Researcher Prof. Ofer Mandelboim of the Hebrew University’s Institute for Medical Research Israel-Canada (IMRIC) and doctoral student Yotam Bar-On have shown that boosting the effectiveness of the body's natural immune system can offset the threat of drug resistant mutations in viral infections. Their discovery could help contain the growing threat of influenza pandemics.More
A recent study by a Hebrew University researcher Prof. Shimon Schuldiner, working in cooperation with German colleagues from the Max Planck Institute, aims at a better understanding of the cell transporter mechanisms that control which substances pass through the cell membrane. While transporter mechanisms block harmful or toxic material, they are also linked to drug resistance. The study's long-term aim is to improve the design of drugs seeking to combat cancer and infectious diseases.More